Amsellem-Ouazana D, Theodore C, Irani J, Bernardini S, Bonnal J-L, Chauvet B, Colombel M, Davin J-L, Laurent G, Lebret T, Maidenberg M, Mazerolles C, Pfister C, Roupret M, Roy C, Rozet F, Saint F, Soulié M, Guillotreau J
Comité de cancérologie de l'AFU - Sous Comité Vessie CCAFU.
Prog Urol. 2010 Mar;20 Suppl 1:S38-40. doi: 10.1016/S1166-7087(10)70024-5.
During the EAU and AUA congress in 2009, major work about the urothelial carcinoma was interested in the classification T1a / b and its therapeutic consequences, the last results of BCG therapy and photodynamic diagnosis. At ASCO congress, the main studies presented focused on the systemic treatment, in adjuvant situation, in first line treatment of metastatic bladder cancer, particularly with the addition of anti-angiogenic to chemotherapy, and in conservative treatment in association with radiotherapy.
在2009年欧洲泌尿外科学会(EAU)和美国泌尿外科学会(AUA)大会期间,关于尿路上皮癌的主要工作集中在T1a / b分类及其治疗后果、卡介苗(BCG)治疗的最新结果以及光动力诊断方面。在美国临床肿瘤学会(ASCO)大会上,所展示的主要研究集中在辅助治疗、转移性膀胱癌一线治疗中的全身治疗,特别是化疗联合抗血管生成药物,以及与放疗联合的保守治疗。